Alder Biopharmaceuticals, Inc. (ALDR)
ALDR Price and Sentiment
ALDR Latest news
Lengo Therapeutics Announces Expansion of its Executive Leadership Team with Appointments in R&D, CMC and Finance2021-09-14 08:00
SAN DIEGO--(BUSINESS WIRE)-- #cancer--Lengo Therapeutics Announces Expansion of its Executive Leadership Team with Appointments in R&D, CMC and Finance
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine2019-10-10 08:01
ALD1910 is Alder’s first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP), a novel target in treating migraine ALD1910 is Alder’s first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP), a novel target in treating migraine
A Denmark-based drugmaker thought the biotech was too cheap to pass up.
Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.
A generous buyout offer has given investors something to cheer about.
Alder BioPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society2019-09-05 16:01
- Data analyses from clinical trials to highlight eptinezumab’s efficacy and early, sustained quality of life improvements in the prevention of chronic migraine -- Preclinical data also to be presented for ALD1910, Alder’s second candidate for migraine, demonstrating its binding and selectivity to pituitary adenylate cyclase-activating peptide -
BOTHELL, Wash., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted an award of 11,500 restricted stock units (“RSUs”) to a new employee under Alder’s 2018 Inducement Award Plan (the “Inducement Plan”), effective August 27, 2019.
Alder BioPharmaceuticals (ALDR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Jim Cramer talks with Alder BioPharmaceuticals CEO Robert Azelby to hear about the development of a migraine drug that’s waiting on FDA approval and how new leadership could improve the stock.